Stem Cell Research Market to 2017 - Strong Pipeline, High Unmet Needs in Chronic Diseases and Favorable Government Policies to Boost Stem Cell R&D
Stem Cell Research Market to 2017 - Strong Pipeline, High Unmet Needs in Chronic Diseases and Favorable Government Policies to Boost Stem Cell R&D
Summary
GBI Research, the leading business intelligence provider, has released its latest research “Stem Cell Research Market to 2017 - Strong Pipeline, High Unmet Needs in Chronic Diseases and Favorable Government Policies to Boost Stem Cell R&D”. The report provides an in-depth analysis on global stem cell research and development. The report suggests investment decisions in stem cell research by providing trends and information on pipelines, federal spending, venture capitalist perspective, country regulations, competitive landscape and market potential. It also provides an analysis on the current investments in various stem cell research segments. In addition to this, the report covers market drivers and challenges for stem cell research and development market.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
GBI Research analysis finds that stem cell therapies have immense market potential driven by strong pipeline that caters to high unmet needs. Increasing investment and supportive regulatory environment in key geographies will help the stem cells industry to realize its full potential. Stem cell therapies high market potential is based on their unique ability to offer curative treatment in comparison to the symptomatic treatment offered by conventional treatments. From a commercial perspective, many diseases that arise as a result of irreversible damage to specialized cell types currently have large unmet needs that cannot be served based on conventional pharmaceutical and biotech research. Not serving these unmet needs results in loss of growth opportunities for the pharmaceutical industry. Stem cell research is a technology that has the potential to serve these unmet needs by providing alternatives to conventional pharmaceutical and biotech research which are targeted more at the symptoms than at the cause.
Strategic partnerships between pharmaceutical companies and stem cell research companies are boosting stem cell research and development. Almost 90% of the drugs in clinical trials fail due to factors such as lack of effectiveness and adverse side effects of the drug. Usually animal or tumor cells are being used and this leads to jury-rigged tests. Hence all major pharmaceutical companies are looking forward for new technologies that increase the possibility to launch new therapies in the market place. At present, there has been a spur in investments from pharmaceutical companies into stem cell research through strategic partnerships with stem cell research companies. Major pharmaceutical companies have planned and aligned their objectives to enter the stem cell market in the next 3-5 years, with a few strategic partnerships already formed between pharmaceutical companies and stem cell research based companies. Pharmaceutical companies are also exploring various methods where stem cells could be utilized in drug discovery process to accelerate the discovery of novel drug molecules.
Scope
Reasons to buy
Summary
GBI Research, the leading business intelligence provider, has released its latest research “Stem Cell Research Market to 2017 - Strong Pipeline, High Unmet Needs in Chronic Diseases and Favorable Government Policies to Boost Stem Cell R&D”. The report provides an in-depth analysis on global stem cell research and development. The report suggests investment decisions in stem cell research by providing trends and information on pipelines, federal spending, venture capitalist perspective, country regulations, competitive landscape and market potential. It also provides an analysis on the current investments in various stem cell research segments. In addition to this, the report covers market drivers and challenges for stem cell research and development market.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
GBI Research analysis finds that stem cell therapies have immense market potential driven by strong pipeline that caters to high unmet needs. Increasing investment and supportive regulatory environment in key geographies will help the stem cells industry to realize its full potential. Stem cell therapies high market potential is based on their unique ability to offer curative treatment in comparison to the symptomatic treatment offered by conventional treatments. From a commercial perspective, many diseases that arise as a result of irreversible damage to specialized cell types currently have large unmet needs that cannot be served based on conventional pharmaceutical and biotech research. Not serving these unmet needs results in loss of growth opportunities for the pharmaceutical industry. Stem cell research is a technology that has the potential to serve these unmet needs by providing alternatives to conventional pharmaceutical and biotech research which are targeted more at the symptoms than at the cause.
Strategic partnerships between pharmaceutical companies and stem cell research companies are boosting stem cell research and development. Almost 90% of the drugs in clinical trials fail due to factors such as lack of effectiveness and adverse side effects of the drug. Usually animal or tumor cells are being used and this leads to jury-rigged tests. Hence all major pharmaceutical companies are looking forward for new technologies that increase the possibility to launch new therapies in the market place. At present, there has been a spur in investments from pharmaceutical companies into stem cell research through strategic partnerships with stem cell research companies. Major pharmaceutical companies have planned and aligned their objectives to enter the stem cell market in the next 3-5 years, with a few strategic partnerships already formed between pharmaceutical companies and stem cell research based companies. Pharmaceutical companies are also exploring various methods where stem cells could be utilized in drug discovery process to accelerate the discovery of novel drug molecules.
Scope
- Country analysis of regulatory framework, investments, research clusters and overall support including the US, the UK, Germany, France, Japan, China, India, Singapore, Canada, and Australia.
- Investment Analysis in leading geographies.
- In-depth information and analysis on the pipeline products expected to bring a shift to the market positions of the leading manufacturers.
- Market characterization data for stem cell research including population size, market potential, NIH funding, technology adoption framework and business models.
- Key drivers and restraints that have a significant impact on the market.
- Competitive landscape of global stem cell research including benchmarking of the leading companies. The key companies discussed in this report are Aastrom Biosciences, Athersys, Bioheart, Aldagen, Mesoblast, Geron Corporation, Advanced Cell Technology, Cytori Therapeutics, Pluristem Therapeutics, Medistem, NeoStem, Helix Therapeutics and StemCells Inc.
- Key M&A activities, licensing agreements, that have taken place between stem cell companies in 2011 till date.
Reasons to buy
- Build effective strategies to launch pipeline products by identifying the latest regulatory developments in the leading geographies
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill their portfolio gaps
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships
- Develop key strategic initiatives by studying the key strategies of top competitors
- Reinforce R&D pipelines by identifying licensing strategies for acquiring new delivery mechanisms that have more efficiency and better safety
Contents
1 TABLE OF CONTENTS1.1 List of Tables
1.2 List of Figures
2 STEM CELL RESEARCH MARKET TO 2017 - INTRODUCTION
2.1 GBI Research Report Guidance
3 STEM CELL RESEARCH MARKET TO 2017- MARKET OVERVIEW
3.1 Stem Cell Research – An Introduction
3.2 Types of Stem Cell Research
3.3 Current Utilization of Different Types of Stem Cells
3.4 Unmet Needs
3.4.1 Applications of Stem Cell Research
4 STEM CELL RESEARCH MARKET TO 2017- MARKET CHARACTERIZATION
4.1 Stem Cell Market – An Introduction
4.2 Market Sizing
4.3 Therapy Cost
4.4 Technology Adoption Framework
4.5 Types of Business Models
4.6 Market Drivers
4.6.1 Immense Market Opportunity for Stem Cell Research for Certain Disorders with High Unmet Need in Terms of Safe and Efficacious Drugs
4.6.2 Encouraging Political Environment on Embryonic Stem Cell Research in the US
4.6.3 Advances in Induced Pluripotent Stem Cells (iPSC) can Decrease Dependency on Embryonic Stem Cells and Increase the Acceptance of Stem Cell Therapy
4.7 Market Barriers & Challenges
4.7.1 High Cost of Research Demands High Investments in the Stem Cell Research and Development
4.7.2 Uncertain Reimbursement Scenario for Stem Cell Therapies Due to High Treatment Cost and Unclear Cost-Benefit Ratio
4.7.3 Ethical, Legal and Social Issues Continue to Remain a Challenge – Albeit with Reduced Impact
4.7.4 Management of Best Scientific Talent for Stem Cell Research Based Companies Remains a Key Area of Focus to Sustain High Quality Research
4.8 Stem Cell Research and Development - Market Trends
4.8.1 Booming Stem Cell Tourism is a Potential Opportunity for Countries to Attract Investments
4.8.2 ASLAP Analysis of Stem Cell Tourism
4.8.3 Federal Funding Support Improves the Stem Cell Research Environment
4.8.4 Increasing Entry of Pharmaceutical Companies Boosts Stem Cell Research & Development
4.8.5 PESTLE Analysis of Stem Cell Research
4.8.6 SWOT Analysis of Stem Cell Research & Development
4.9 Market Analysis
5 STEM CELL RESEARCH MARKET TO 2017 - PIPELINE ANALYSIS
5.1 Discovery
5.2 IND Filed
5.3 Pre-Clinical
5.4 Phase I
5.5 Phase II
5.6 Phase III
6 STEM CELL RESEARCH MARKET TO 2017 - INVESTMENT TRENDS
6.1 Investor’s Perspective on Stem Cell Research
6.1.1 Status of Research
6.1.2 Regulatory Position
6.1.3 Clinical Development
6.1.4 Commercial Models
6.1.5 Patent Policy
6.2 NIH Spending in Stem Cell Research and Development is Increasing and is Supportive
6.2.1 NIH Spending by Therapeutic Areas
6.2.2 High Budget Projects Funded by NIH
6.3 BBSRC Funding in Stem Cell Research
7 STEM CELL RESEARCH MARKET TO 2017 - GEOGRAPHICAL TRENDS
7.1 Stem Cell Companies by Geographic Regions
7.2 The US
7.3 The UK
7.4 China
7.5 Netherlands
7.6 Singapore
7.7 South Korea
7.8 Japan
7.9 India
7.10 Sweden
7.11 Denmark
7.12 France
7.13 Germany
7.14 Israel
7.15 Australia
7.16 Canada
7.17 Czech Republic
8 STEM CELL RESEARCH MARKET TO 2017 - MERGERS AND ACQUISITIONS
8.1 Mergers and Acquisitions
8.1.1 Overview
8.1.2 Segmentation by Type
8.1.3 Segmentation by Region
8.2 Licensing Agreements and Co-Development
8.2.1 Segmentation by Region
8.2.2 Segmentation by Deal Type
9 STEM CELL RESEARCH MARKET TO 2017 - COMPANY PROFILES
9.1 Aastrom Biosciences
9.2 Athersys Inc.
9.3 Osiris Therapeutics
9.4 Bioheart
9.5 Aldagen
9.6 Mesoblast
9.7 Geron
9.8 Advanced Cell Technology
9.9 Cytori Therapeutics
9.10 Pluristem Therapeutics
9.11 Medistem
9.12 NeoStem
9.13 Helix Therapeutics
9.14 StemCells Inc.
10 STEM CELL RESEARCH MARKET TO 2017- UNIVERSITY PROFILES
10.1 University of California, San Francisco
10.2 University of Washington
11 STEM CELL RESEARCH MARKET TO 2017 - CONCLUSION
12 STEM CELL RESEARCH MARKET TO 2017- APPENDIX
12.1 Market Definitions
12.2 Abbreviations
12.3 Methodology
12.3.1 Coverage
12.3.2 Secondary Research
12.3.3 Primary Research
12.3.4 Expert Panels
12.4 Contact Us
12.5 Disclaimer
12.6 Sources
LIST OF TABLES
Table 1: Stem Cell Research Market to 2017, Global Sales of Stem Cells, $bn, 2008-2014
Table 2: Stem Cell Research Market to 2017, Disease Conditions and Prevalence in the US, 2010
Table 3: Stem Cell Research Market to 2017, Preferred Countries for Stem Cell Tourism, 2011
Table 4: Stem Cell Research Market to 2017, Pharmaceutical Companies Partnership Environment, 2010-2011
Table 5: Stem Cell Research Market to 2017, Pipeline Analysis, Discovery, 2011
Table 6: Stem Cell Research Market to 2017, Pipeline Analysis, IND Filed, 2011
Table 7: Stem Cell Research Market to 2017, Pipeline Analysis, Preclinical, 2011
Table 8: Stem Cell Research Market to 2017, Pipeline Analysis, Phase I, 2011
Table 9: Stem Cell Research Market to 2017, Pipeline Analysis, Phase II, 2011
Table 10: Stem Cell Research Market to 2017, Pipeline Analysis, Phase III, 2011
Table 11: Stem Cell Research Market to 2017, the US, NIH Funding, $m, 2002-2010
Table 12: Stem Cell Research Market to 2017, NIH Funding, Cardiovascular, ($m), 2009-2010
Table 13: Stem Cell Research Market to 2017, NIH Funding, Central Nervous System, ($m), 2009-2010
Table 14: Stem Cell Research Market to 2017, NIH Funding, Genetic Disorders, ($m), 2009-2010
Table 15: Stem Cell Research Market to 2017, NIH Funding, Hematological Disorders, ($m), 2009-2010
Table 16: Stem Cell Research Market to 2017, NIH Funding, Oncology, ($m), 2009-2010
Table 17: Stem Cell Research Market to 2017, NIH Funding, Basic Research, ($m), 2009-2010
Table 18: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2009 – May 2011
Table 19: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2009
Table 20: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2010
Table 21: Stem Cell Research Market to 2017, Segmentation of Funding Mechanisms by Value ($m), 2009
Table 22: Stem Cell Research Market to 2017, Segmentation of Funding Mechanisms by Value ($m), 2010
Table 23: Stem Cell Research Market to 2017, Segmentation by Funding Mechanism in Therapeutic Areas, 2010
Table 24: Stem Cell Research Market to 2017, Acquisitions, 2011
Table 25: Stem Cell Research Market to 2017, Aastrom BioSciences Inc., 2011
Table 26: Stem Cell Research Market to 2017, Athersys Inc., 2011
Table 27: Stem Cell Research Market to 2017, Osiris Therapeutics, 2011
Table 28: Stem Cell Research Market to 2017, Bioheart, 2011
Table 29: Stem Cell Research Market to 2017, Aldagen, 2011
Table 30: Stem Cell Research Market to 2017, Mesoblast, 2011
Table 31: Stem Cell Research Market to 2017, Geron, 2011
Table 32: Stem Cell Research Market to 2017, Advanced Cell Technology, 2011
Table 33: Stem Cell Research Market to 2017, Cytori Therapeutics, 2011
Table 34: Stem Cell Research Market to 2017, Pluristem Therapeutics, 2011
Table 35: Stem Cell Research Market to 2017, Medistem, 2011
Table 36: Stem Cell Research Market to 2017, NeoStem, 2011
Table 37: Stem Cell Research Market to 2017, Helix Therapeutics, 2011
Table 38: Stem Cell Research Market to 2017, StemCells Inc., 2011
Table 39: Stem Cell Research Market to 2017, University of California, San Francisco, 2011
Table 40: Stem Cell Research Market to 2017, University of Washington, 2011
LIST OF FIGURES
Figure 1: Stem Cell Research Market to 2017, Stem Cell Research and Development, 2010
Figure 2: Stem Cell Research Market to 2017, Current Utilization of Different Types of Stem Cells, 2010
Figure 3: Stem Cell Research Market to 2017, Stem Cells – Interaction Framework, 2011
Figure 4: Stem Cells Research Market to 2017, Cells Models –Present and the Future, 2011
Figure 5: Stem Cell Research Market to 2017, Unmet Need vs Time to Market, 2010-2017
Figure 6: Stem Cell Research Market to 2017, Applications of Stem Cell Research, 2011
Figure 7: Stem Cell Research Market to 2017, Global Sales of Stem Cells, $bn, 2008-2014
Figure 8: Stem Cell Research Market to 2017, Technology Adoption Framework, 2011
Figure 9: Stem Cell Research Market to 2017, Business Models in Stem Cell Industry, 2011
Figure 10: Stem Cell Research Market to 2017, Treatment Availability – Impact Analysis, 2011
Figure 11: Stem Cell Research Market to 2017, Political Environnent – Impact Analysis, 2011
Figure 12: Stem Cell Research Market to 2017, Advances in iPSC – Impact Analysis, 2011
Figure 13: Stem Cell Research Market to 2017, High Cost of Research – Impact Analysis, 2011
Figure 14: Stem Cell Research Market to 2017, Reimbursements – Impact Analysis, 2011
Figure 15: Stem Cell Research Market to 2017, Ethical, Legal and Social Issues – Impact Analysis, 2011
Figure 16: Stem Cell Research Market to 2017, Human Resources – Impact Analysis, 2011
Figure 17: Stem Cell Research Market to 2017, ASLAP Analysis of Stem Cell Tourism, 2011
Figure 18: Stem Cell Research Market to 2017, Federal Funding Trend, 2010
Figure 19: Stem Cell Research Market to 2017, PESTLE Analysis of Stem Cell Research, 2011
Figure 20: Stem Cell Research Market to 2017, SWOT Analysis of Stem Cell Research and Development, 2011
Figure 21: Stem Cell Research Market to 2017, SWOT Analysis of Stem Cell Research and Development – Impact Grid in 2010
Figure 22: Stem Cell Research Market to 2017, Porter’s Five Force Analysis, 2011
Figure 23: Stem Cell Research Market to 2017, Venture Capitalist’s Perspective on Stem Cell Research, 2011
Figure 24: Stem Cell Research Market to 2017, VC’s Perspective on Stem Cell Research – Impact Analysis, 2011
Figure 25: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2009 – May 2011
Figure 26: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2009
Figure 27: Stem Cell Research Market to 2017, Segmentation of Funding Received by Therapeutic Areas, 2010
Figure 28: Stem Cell Research Market to 2017, Segmentation of Funding Mechanisms by Value ($m), 2009
Figure 29: Stem Cell Research Market to 2017, Segmentation of Funding Mechanisms by Value ($m), 2010
Figure 30: Stem Cell Research Market to 2017, Segmentation of Total Value of Funding by Therapeutic Areas, 2009
Figure 31: Stem Cell Research Market to 2017, Segmentation of Total Value of Funding by Therapeutic Areas, 2010
Figure 32: Stem Cell Research Market to 2017, Segmentation of Total Value by the Funding Mechanisms, 2009
Figure 33: Stem Cell Research Market to 2017, Segmentation of Total Value by Funding Mechanisms, 2010
Figure 34: Stem Cell Research Market to 2017, Segmentation by Funding Mechanism in Therapeutic Areas, 2010
Figure 35: Stem Cell Research Market to 2017, Stem Cell Companies by Geographic Regions, 2010
Figure 36: Stem Cell Research Market to 2017, Country Analysis – The US
Figure 37: Stem Cell Research Market to 2017, Country Analysis – The UK, 2011
Figure 38: Stem Cell Research Market to 2017, Country Analysis- China, 2011
Figure 39: Stem Cell Research Market to 2017, Country Analysis – Netherlands, 2011
Figure 40: Stem Cell Research Market to 2017, Country Analysis – Singapore, 2011
Figure 41: Stem Cells Research Market to 2017, Country Analysis – South Korea, 2011
Figure 42: Stem Cell Research Market to 2017, Country Analysis – Japan, 2011
Figure 43: Stem Cell Research Market to 2017, Country Analysis – India, 2011
Figure 44: Stem Cell Research Market to 2017, Country Analysis – Sweden, 2011
Figure 45: Stem Cell Research Market to 2017, Country Analysis – Denmark, 2011
Figure 46: Stem Cell Research Market to 2017, Country Analysis – France, 2011
Figure 47: Stem Cell Research Market to 2017, Country Analysis – Germany, 2011
Figure 48: Stem Cells Research Market to 2017, Country Analysis – Israel, 2011
Figure 49: Stem Cell Research Market to 2017, Country Analysis – Australia, 2011
Figure 50: Stem Cell Research Market to 2017, Country Analysis – Canada, 2011
Figure 51: Stem Cells Research Market to 2017, Country Analysis – Czech Republic, 2011
Figure 52: Stem Cell Research Market to 2017, Segmentation of Licensing Deal Value by Deal Type, 2004- May 2011
Figure 53: Stem Cell Research Market to 2017, Segmentation of Number of Licensing Deals by Deal Type, 2004- May 2011
Figure 54: Stem Cell Research Market to 2017, Segmentation of Licensing Deals Value by Region, 2004 – May 2011
Figure 55: Stem Cell Research Market to 2017, Segmentation of Number of Licensing Deals by Region, 2004 – May 2011
Figure 56: Stem Cell Research Market to 2017, Segmentation of Licensing Deal Value by Region, 2004 – May 2011
Figure 57: Stem Cell Research Market to 2017, Segmentation of Number of Licensing Deals by Region, 2004 – May 2011
Figure 58: Stem Cell Research Market to 2017, Segmentation of Licensing Deal Value by Deal Type, 2004 – May 2011
Figure 59: Stem Cell Research Market to 2017, Segmentation of Number of Licensing Deals by Deal Type, 2004 – May 2011
COMPANIES MENTIONED
Aastrom Biosciences
Athersys Inc.
Osiris Therapeutics
Bioheart
Aldagen
Mesoblast
Geron
Advanced Cell Technology
Cytori Therapeutics
Pluristem Therapeutics
Medistem
NeoStem
Helix Therapeutics
StemCells Inc. Skip to top